Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.
about
Pharmacogenetics education in British medical schoolsPharmacogenetics and anaesthesia: the value of genetic profilingPharmacogenomics discovery and implementation in genome-wide association studies eraClinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingEffects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysisPersonalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicineEffect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysisAnalysis of pharmacogenomic variants associated with population differentiationThe Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics StudyWarfarin genotyping with hybridization-induced aggregation on a poly(ethylene terephthalate) microdevice.Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.Rapid genotyping of single nucleotide polymorphisms influencing warfarin drug response by surface-enhanced laser desorption and ionization time-of-flight (SELDI-TOF) mass spectrometry.Warfarin pharmacogenomicsAn Assessment of Osteoporotic Conditions among Users and Non-Users of Warfarin: A Case-Control Study.Characteristics of ambulatory anticoagulant adverse drug events: a descriptive studyValidation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testingEvaluation of risk factors in patients with vitamin K-dependent coagulopathy presumed to be caused by exposure to brodifacoum.Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans.Only connect: personal genomics and the future of American medicine.Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.Drug-gene interactions: inherent variability in drug maintenance dose requirementsChapter 11: challenges in and principles for conducting systematic reviews of genetic tests used as predictive indicators.Pathway analysis of genome-wide data improves warfarin dose prediction.Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model.Warfarin dosage response related pharmacogenetics in Chinese population.Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.Genetic warfarin dosing: tables versus algorithms.Assessment of the pharmacogenomics educational needs of pharmacists.Bioinformatics challenges for personalized medicineThe use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range?Warfarin toxicity and individual variability-clinical case.Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.Impact of polymorphisms of the GGCX gene on maintenance warfarin dose in Chinese populations: Systematic review and meta-analysisRelating human genetic variation to variation in drug responses.Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.Development and evaluation of a pharmacogenomics educational program for pharmacistsGenetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population.A genome-wide scan for common genetic variants with a large influence on warfarin maintenance doseThe largest prospective warfarin-treated cohort supports genetic forecastingA cardiovascular phenotype in warfarin-resistant Vkorc1 mutant rats
P2860
Q24289489-A776073A-150B-4B49-AF01-B4204BA289FDQ26859221-DFE77774-5663-47FC-A023-5E38DC314CA9Q27001573-7D429264-5783-4EB2-8E72-2A6C879A20E4Q27008360-0C0E1613-4488-483C-AB4D-1B8EECA1DFDBQ27026134-BE0AF14E-0934-4C81-A242-513DE10C21ACQ28082746-2F62EEAE-610F-4A9F-948D-2C7C898E8ADDQ28276605-BF543112-1314-4B7C-AEF4-5FA0CA3DA581Q28544983-136B390C-DDED-48BD-9CF1-F147F685A2B0Q28553937-C0CBDC5E-9384-462D-A98A-5B029CAF7D4CQ30275196-69ED8D31-23D2-4EF2-BA52-80F4E20942F3Q31131437-903AF179-690D-453E-8A12-1D20FF791674Q33523960-B2E63A88-0583-4EF8-93AD-BCC125F97B32Q33561482-1FCABA20-D6F1-488E-98B5-0858D57091C8Q33666570-45EF1DFF-ABAB-4DED-A0CA-4EF9EB751A6EQ33745957-165320B4-888F-4598-938D-44DDA9141566Q33813830-5748AB20-5C18-4A8E-8B76-605F64A483E2Q33912911-1894F342-C416-40C6-AFB9-BD4735DE0191Q33978811-B326B8B2-45BA-475C-83DF-529891EC22A0Q33983987-15EF65E9-7E40-4A71-A0CD-F379489D01D9Q33990441-3347C786-813D-435C-BEDE-2FDF8D207318Q34154939-9F6A021E-3C76-4CC4-BDA0-339E54F56699Q34287019-76289E02-6FF6-495A-A114-313173D9998DQ34790566-7D2BCBE1-3D80-44ED-9620-032BF4F14F9EQ34834319-42CBCAF2-4561-4DD7-AE31-8B45D59488B8Q34977531-2758C031-2B86-4DFD-8CCF-6FED1C69C899Q34994877-D79689D3-64A0-4C08-99CE-622C934C505CQ35021027-FA143EB8-4FB8-4FB3-8347-76FC9DE18800Q35030197-1703302B-C1BB-4D99-87F2-7F80115325A4Q35051893-A35AEAE8-0D52-4AA1-8620-F1BFE5FC5449Q35071798-7B4E8838-B496-422D-8222-2971C80571D2Q35155651-0BF12126-8C48-4951-8709-94D3B8B62F94Q35219654-6425D267-30BE-4BC7-84AF-2C1B4452F6E9Q35757323-6BC9B788-03D2-4CD2-8613-0F424988EFB9Q36252524-11D039FC-87DB-42D2-8831-4F8253323E36Q36475190-4D8E456A-7C58-4441-A2A7-1DD2786DFC0AQ36626572-FE1F8E1C-94BB-4AB3-9685-124FD160FFACQ36813817-FDF34A0F-8528-4999-BE7D-1ED5FFBAAF76Q36835176-6CAE41F9-C3F8-4384-B9E7-44DECED12432Q37071087-37CBD0C3-9FB0-44BC-8BDF-E0F2AF7B14E2Q37088955-CD35C3D8-0A8E-4EE7-9B71-C43B6946DFF4
P2860
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.
@en
type
label
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.
@en
prefLabel
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.
@en
P2860
P1476
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.
@en
P2093
Brian F Gage
Lawrence J Lesko
P2860
P2888
P356
10.1007/S11239-007-0104-Y
P577
2007-10-01T00:00:00Z